Clinical trial NCT06948006: A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
Official title: An Open-label, Randomised, 2-arm, 3-period, 6-treatment Single-dose, Crossover Study Comparing the Pharmacokinetics of 2 Different Formulations of AZD4144, and Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Participants
Keywords: Cardiorenal disease
Food effect
Proton-pump inhibitor
Pharmacokinetics
Tablet formulation
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Parexel
First posted: 2025-04-28
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The main aim of this study to compare the pharmacokinetics (PK) of two formulations of AZD4144 and assess the effect of food and omeprazole on PK of AZD4144 in healthy participants.

Detailed description: This is an open-label, randomized, single-dose, crossover Phase I study.

The study will comprise:

1. A Screening Period of 28 days.
2. Three Residential Periods
3. A final Follow-up period within 7 to 10 days after the last dose of study drug. There will be a minimum washout period of 7 days between each AZD4144 dose.

This study includes the following 2 arms:

Arm 1 consists of 3 treatments:

1. Treatment A: AZD4144 dose 1 as tablet (under fasted condition)
2. Treatment B: AZD4144 dose 1 as tablet (under fed condition)
3. Treatment C: AZD4144 dose 1 as an oral solution (under fasted condition)

Arm 2 consists of 3 treatments:

1. Treatment D: AZD4144 dose 2 as tablet (under fasted condition)
2. Treatment E: AZD4144 dose 2 as tablet (under fed condition)
3. Treatment F: Omeprazole once daily for 4 days, followed by a single dose of omeprazole along with a single dose of AZD4144 dose 2 as tablet (under fasted condition).

The participants will be randomised to one of the following treatment sequences:

Arm 1: ABC, BCA or CAB Arm 2: DEF or EDF

Eligibility criteria: Inclusion Criteria:

1. Signed the informed consent form before any study-related procedure.
2. Healthy male and female participants with suitable veins for cannulation or repeated venipuncture.
3. Negative pregnancy test for females at screening, first admission, and follow-up.
4. Females of childbearing potential must use highly effective contraception from first dose until 3 months after last dose.
5. Non-childbearing potential females must meet postmenopausal or surgical sterilization criteria.
6. Sexually active fertile males must use contraception from first dose until 3 months after last dose.
7. Body Mass Index (BMI) between 18-32 kg/m2 and weight ≥45 kg at screening and first admission.

Exclusion Criteria:

1. History of any clinically important disease or disorder that may put the participant at risk or influence study results.
2. History or presence of gastrointestinal, hepatic, or renal disease or any condition affecting drug absorption, distribution, metabolism, or excretion.
3. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of randomization.
4. Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing or presence of fever within 14 days prior to dosing.
5. Clinically significant serious active and chronic infections within 60 days prior to randomization.
6. Any history or evidence of tuberculosis (TB) (active or latent) using TB-QuantiFERON tests during screening.
7. Clinical signs and symptoms consistent with coronavirus disease 2019 (COVID-19).
8. Known history of primary immunodeficiency or an underlying condition that predisposes to infection.
9. Positive result for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV).
10. Plasma donation within one month of the screening visit or any blood donation/blood loss \> 500 mL during the 3 months prior to the screening visit.
11. Participants who have previously received AZD4144.

Primary outcomes:
measure: Area under concentration-time curve from time 0 to infinity (AUCinf) of AZD4144
timeFrame: Days 1-4, Days 8-11 and Days 15-18
measure: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD4144
timeFrame: Days 1-4, Days 8-11 and Days 15-18
measure: Maximum observed drug concentration (Cmax) of AZD4144
timeFrame: Days 1-4, Days 8-11 and Days 15-18
Secondary outcomes:
measure: Number of participants with adverse events (AEs)
timeFrame: From Day 1 to Day 25
measure: Number of participants with serious AEs
timeFrame: From Screening (Day -28 to Day -2) to Day 25
Other outcomes:
Locations:
city: Harrow
country: United Kingdom
facility: Research Site
Study officials:
References: